Daxor Validates BVA’s 20% Hourly Albumin Leak Detection in Heart Failure Study
Daxor’s Blood Volume Analyzer measured a median 20% per hour albumin escape rate in a heart failure cohort, while four standard clinical indices showed uniformly low scores. The data confirms BVA’s unique mechanistic specificity and positions it as the only bedside tool for direct capillary leak quantification.
1. Clinical Data Presentation
At the SCCM 2026 Critical Care Congress, Daxor presented clinical data evaluating its Blood Volume Analyzer in a heart failure cohort, directly measuring albumin escape as a proxy for capillary leak using in-vivo AER metrics.
2. Comparative Accuracy Findings
The BVA system recorded a median albumin escape rate of 20% per hour, while four established clinical indices, including the Capillary Leak Index and SOFA score, showed weak, non-significant correlations with actual leak measurements.
3. Market and Commercial Impact
These findings validate BVA’s unique mechanistic specificity for direct capillary leak quantification, reinforcing Daxor’s position as the sole provider of bedside albumin leak rate analysis and supporting broader adoption in critical care and heart failure markets.